JPWO2022063803A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022063803A5
JPWO2022063803A5 JP2023518392A JP2023518392A JPWO2022063803A5 JP WO2022063803 A5 JPWO2022063803 A5 JP WO2022063803A5 JP 2023518392 A JP2023518392 A JP 2023518392A JP 2023518392 A JP2023518392 A JP 2023518392A JP WO2022063803 A5 JPWO2022063803 A5 JP WO2022063803A5
Authority
JP
Japan
Prior art keywords
seq
cell
bispecific antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542212A (ja
JP2023542212A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075995 external-priority patent/WO2022063803A1/en
Publication of JP2023542212A publication Critical patent/JP2023542212A/ja
Publication of JPWO2022063803A5 publication Critical patent/JPWO2022063803A5/ja
Publication of JP2023542212A5 publication Critical patent/JP2023542212A5/ja
Pending legal-status Critical Current

Links

JP2023518392A 2020-09-24 2021-09-22 T細胞二重特異性抗体に関連する有害作用の予防又は緩和 Pending JP2023542212A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20198050.5 2020-09-24
EP20198050 2020-09-24
EP20201583.0 2020-10-13
EP20201583 2020-10-13
EP21172627 2021-05-07
EP21172627.8 2021-05-07
PCT/EP2021/075995 WO2022063803A1 (en) 2020-09-24 2021-09-22 Prevention or mitigation of t-cell bispecific antibody-related adverse effects

Publications (3)

Publication Number Publication Date
JP2023542212A JP2023542212A (ja) 2023-10-05
JPWO2022063803A5 true JPWO2022063803A5 (https=) 2024-09-30
JP2023542212A5 JP2023542212A5 (https=) 2024-09-30

Family

ID=78000677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518392A Pending JP2023542212A (ja) 2020-09-24 2021-09-22 T細胞二重特異性抗体に関連する有害作用の予防又は緩和

Country Status (12)

Country Link
US (1) US20220088195A1 (https=)
EP (1) EP4216998A1 (https=)
JP (1) JP2023542212A (https=)
KR (1) KR20230074146A (https=)
CN (1) CN116322691A (https=)
AU (1) AU2021350075A1 (https=)
BR (1) BR112023005399A2 (https=)
CA (1) CA3193478A1 (https=)
IL (1) IL300543A (https=)
MX (1) MX2023003133A (https=)
TW (1) TW202228773A (https=)
WO (1) WO2022063803A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
JP2025539760A (ja) * 2022-11-15 2025-12-09 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合分子

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
JP6553069B2 (ja) * 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗wt1/hla二重特異性抗体
JP6464255B2 (ja) 2014-08-04 2019-02-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性t細胞活性化抗原結合分子
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
WO2018183888A2 (en) * 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CN111699001A (zh) * 2017-12-07 2020-09-22 尤利乌斯·马克西米利安维尔茨堡大学 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节
SG11202005632SA (en) * 2017-12-21 2020-07-29 Hoffmann La Roche Antibodies binding to hla-a2/wt1
EP3863644A4 (en) * 2018-10-12 2022-10-05 Jeanmarie Guenot CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES

Similar Documents

Publication Publication Date Title
JP2022050618A5 (https=)
JP2024156736A5 (https=)
Armuzzi et al. Infliximab in the treatment of steroid-dependent ulcerative colitis
JP2021528423A5 (https=)
JP2019515008A5 (https=)
FI3394103T3 (fi) Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon
HRP20220014T1 (hr) Postupci liječenja raka kože davanjem inhibitora pd-1
JP2008540447A5 (https=)
RU2015144666A (ru) Терапия для лечения рака, включающая антитела против клаудина 18.2
JP2009518441A5 (https=)
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
Österborg et al. Strategies in the management of alemtuzumab-related side effects
JP2021512107A5 (https=)
JP2024507283A (ja) 抗腫瘍薬を調製するための免疫療法薬と併用でのppar-デルタ阻害剤の使用
JP2015172060A5 (https=)
Danese et al. Biological Therapies for Inflammatory Bowel Disease: Research DrivesClinics
JPWO2017172771A5 (https=)
JPWO2022063803A5 (https=)
CN111166878A (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
Martin Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis
JP2020521798A5 (https=)
Badn et al. Inhibition of Inducible Nitric Oxide Synthase Enhances Anti‐tumour Immune Responses in Rats Immunized with IFN‐γ‐Secreting Glioma Cells
CN117693350A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
KR102944563B1 (ko) 종양 치료용 약물의 제조에서 파미티닙과 조합된 항-pd-1 항체의 용도